A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of two doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus Save

Date Added
November 8th, 2016
PRO Number
Eric Zollars
Autoimmune disease, Lupus

The purpose of this study is to determine whether the addition of Anifrolumab (MEDI 546) to a patient's current Lupus treatment is effective in reducing Lupus disease activity.

Lupus is an autoimmune disease, which means that your immune system not only attacks bacteria and viruses but also attacks your healthy cells and organs, affecting many parts of the body. Lupus can cause fever, joint pain, rash (redness of the skin), sensitivity of the skin to sunlight, as well as other symptoms, and may lead to inflammation and organ damage.

Current treatments for Lupus are mainly drugs that suppress the immune system such as cortisone-like drugs (such as prednisone) and cyclophosphamide (a potent drug sometimes used in treating certain types of cancer), and drugs commonly used to treat or prevent malaria (called antimalarials) such as hydroxychloroquine. Many of these treatments may have serious side effects if used for a long time. Therefore, there is a need for new and effective treatments for Lupus.

Recruitment Contact
Angela Robinson


-- OR --